WASHINGTON — Hospitals for years have complained that Medicare pays so little for CAR-T cancer treatments that they sometimes lose money administering the incredibly expensive treatments. But that could soon change: if drug companies succeed in making the cancer treatments safer, hospitals could provide them more often in outpatient departments, where payment is higher.
CAR-T uses the body’s own immune system to kill cancerous cells. The procedure, regulated as a drug, involves taking T cells from a patient’s blood, adding chimeric antigen receptors (CAR) to the T cells that kill cancer, and injecting the CAR-T treatment back into the patient.
It’s worked wonders in many cancer patients who have run out of options. But right now it’s almost exclusively administered in hospitals, because the side effects can require aggressive treatments. In many cases, the CAR-T cells trigger immune reactions that can be life-threatening.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.